Yeah, it's not a brand new study, but it covers a topic of "new" hysteria on the board.
http://www.vaccines.mil/documents/library/MF59.pdf"Squalene is a naturally occurring oil which has been used in the development of vaccine adjuvants, such as
the oil-in-water emulsion MF59. In past years, by use of noncontrolled and nonvalidated assays, a claim was
made that antisqualene antibodies were detectable in the sera of individuals with the so-called Gulf War
syndrome. Using a validated enzyme-linked immunosorbent assay for the quantitation of immunoglobulin G
(IgG) and IgM antibodies against squalene, we demonstrated that antisqualene antibodies are frequently
detectable at very low titers in the sera of subjects who were never immunized with vaccines containing
squalene. More importantly, vaccination with a subunit influenza vaccine with the MF59 adjuvant neither
induced antisqualene antibodies nor enhanced preexisting antisqualene antibody titers. In conclusion, antisqualene
antibodies are not increased by immunization with vaccines with the MF59 adjuvant. These data
extend the safety profile of the MF59 emulsion adjuvant."
---------------------------------------------------------------------------------------------------------------------------
More on the matter:
Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly
http://www.ncbi.nlm.nih.gov/pubmed/19040034Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TD4-3X115S9-N&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_searchStrId=1038702152&_rerunOrigin=google&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=d4919d40a4d3bd83143c024700653f7cA Phase II, randomized, controlled, observer-blind, single-center study to evaluate the immunogenicity,
safety and tolerability of two doses of MF59®-adjuvanted H5N1 influenza vaccine, AFLUNOV®, in
subjects aged 6 months to 17 years
http://www.who.int/vaccine_research/immunogenicity/82_astractvisicari.pdf